IRON
Disc Medicine, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1.12M | $73.28M | n/a | n/a |
| Q2 2026 | 83 | +7 | 22.99M | $1.68B | +9 | −2 |
| Q1 2026 | 79 | +1 | 22.38M | $1.43B | +7 | −6 |
| Q4 2025 | 77 | -1 | 22.10M | $1.75B | +1 | −2 |
| Q3 2025 | 17 | +3 | 15.61M | $1.03B | +3 | n/a |
| Q2 2025 | 11 | -1 | 11.75M | $622.02M | +1 | −2 |
| Q1 2025 | 9 | -1 | 6.07M | $301.51M | n/a | −1 |
| Q4 2024 | 10 | +3 | 5.16M | $327.26M | +3 | n/a |
| Q3 2024 | 6 | -1 | 5.16M | $253.75M | n/a | −1 |
| Q2 2024 | 7 | n/a | 5.00M | $225.18M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 1.76M | n/a | $79.17M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | T. Rowe Price ✦ | 1.12M | n/a | $50.58M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Point72 Asset Management ✦ | 761.43K | n/a | $34.32M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 618.50K | n/a | $27.88M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 403.74K | n/a | $18.20M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Citadel Advisors ✦ | 321.52K | n/a | $14.49M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Marshall Wace ✦ | 12.30K | n/a | $554,361 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 203 holders, 40.63M shares, $2.48B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 27.14K sh · $1.90M
Director · 759 sh · $60,690
Director · 18 sh · $1,439
Director · 912 sh · $72,924
Director · 2.34K sh · $187,073
Director · 54 sh · $4,319
Director · 2.81K sh · $224,744
Director · 511 sh · $40,967
Director · 26.54K sh · $2.13M
Director · 22.09K sh · $1.77M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology